Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học 'Respiratory Research cung cấp cho các bạn kiến thức về ngành y đề tài: Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive review. | Respiratory Research BioMed Central Review Open Access Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids a comprehensive review Hannu Kankaanranta 1 2 Aarne Lahdensuo2 Eeva Moilanen1 3 and Peter J Barnes4 Address 1Frhe Immunopharmacological Research Group Medical School University of Tampere Tampere Finland 2Department of Pulmonary Diseases Tampere University Hospital Tampere Finland 3Department of Clinical Chemistry Tampere University Hospital Tampere Finland and 4Department of Thoracic Medicine National Heart and Lung Institute Imperial College London UK Email Hannu Kankaanranta - blhaka@ Aarne Lahdensuo - EevaMoilanen - Peter J Barnes - Corresponding author Published 27 October 2004 Received 02 June 2004 Respiratory Research 2004 5 17 doi 1465-9921-5-17 Accepted 27 October 2004 This article is available from http content 5 1 17 2004 Kankaanranta et al licensee BioMed Central Ltd. This is an open-access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Many patients with persistent asthma can be controlled with inhaled corticosteroids ICS . However a considerable proportion of patients remain symptomatic despite the use of ICS. We present systematically evidence that supports the different treatment options. A literature search was made of Medline PubMed to identify randomised and blinded trials. To demonstrate the benefit that can be obtained by increasing the dose of ICS dose-response studies with at least three different ICS doses were identified. To demonstrate whether more benefit can be obtained by adding long-acting P2-agonist LABA leukotriene antagonist LTRA or theophylline than by increasing the dose of ICS .
